Recent insights on chronic heart failure, cachexia and nutrition

Miján-de-la-Torre, Alberto

doi:10.1097/mco.0b013e32832a2171

Cited by 18 publications

(12 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26,27 Chronic disease and/or cachexia are also associated with anemia and are known to increase SNS, but the patients in our study did not present these states. 28 Finally, we excluded iron deficiency and drug adverse effects. Renin angiotensin system blockers and ␤-blockers are known to be associated with anemia, but their distribution was similar in both groups.…”

Section: Discussionmentioning

confidence: 99%

Tonic Chemoreflex Activation Contributes to Increased Sympathetic Nerve Activity in Heart Failure–Related Anemia

et al. 2010

View full text Add to dashboard Cite

Abstract-Sympathetic activation contributes to both the initiation and progression of heart failure. The role of anemia in determining sympathetic overactivity in chronic heart failure (CHF) patients is unknown. We tested the hypothesis that, in CHF patients, anemia could lead to increased sympathetic activity through tonic activation of excitatory chemoreceptor afferents. We conducted a double-blind, randomized, vehicle-controlled study to examine the effect of chemoreflex deactivation on muscle sympathetic nerve activity in CHF patients with and without anemia. We compared the effect of breathing 100% oxygen for 15 minutes in 18 stable CHF patients with anemia and 18 control CHF patients matched for age, sex, blood pressure, and body mass index. Baseline muscle sympathetic nerve activity was significantly elevated in CHF patients with anemia compared with patients with CHF alone (56.0Ϯ3.2 versus 45.5Ϯ3.1 bursts per minute; PϽ0.0237). Administration of 100% oxygen led to a significant decrease in muscle sympathetic nerve activity in CHF patients with anemia (from 56.0Ϯ3.4 to 50.9Ϯ3.2 bursts per minute; PϽ0.0019). In contrast, neither room air nor 100% oxygen changed muscle sympathetic nerve activity or hemodynamics in patients with CHF alone. We report for the first time direct evidence of increased sympathetic nerve traffic in patients with CHF-related anemia. Sympathetic hyperactivity in patients with CHF and anemia is partially chemoreflex mediated and could explain how anemia contributes to the progression of CHF and increases morbidity and mortality in these patients. (Hypertension. 2010;55:1012-1017.)

show abstract

Section: Discussionmentioning

confidence: 99%

Tonic Chemoreflex Activation Contributes to Increased Sympathetic Nerve Activity in Heart Failure–Related Anemia

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In addition, patients with CHF and cachexia have a death rate that has been estimated to be as high as 50% over a period of 18 mo (4,5,15). Acquired GH resistance appears to occur in these individuals (4,5,16). In several small randomized trials, GH treatment failed to improve the clinical status of CHF patients (17)(18)(19).…”

Section: Gh In Cachexia Induced By Pulmonary and Cardiac Diseasementioning

confidence: 99%

“…Cachexia occurs in '20% of patients with CHF (4,5). In addition, patients with CHF and cachexia have a death rate that has been estimated to be as high as 50% over a period of 18 mo (4,5,15).…”

Section: Gh In Cachexia Induced By Pulmonary and Cardiac Diseasementioning

confidence: 99%

“…Cachexia is associated with increased death and morbidities, which include skeletal muscle weakness and impaired muscle work capacity, prolonged convalescence, and increased risk of infection (2,4,5,7). In 2006, it was estimated that '5 million people with these conditions in the United States were cachectic because of cancer and other major causes (2).…”

Section: Introductionmentioning

confidence: 99%

“…Cachexia, or wasting, is the progressive loss of skeletal muscle and adipose tissue associated with fatigue and weakness commonly observed in multiple disease states, which include cancer, AIDS, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), and chronic renal failure (1)(2)(3)(4)(5). Body tissue wasting in cachexic patients is likely multifactorial and is potentially due to a number of complex factors, which include anorexia and early satiety, blunted muscle protein synthesis, increased muscle protein breakdown, enhanced lipolysis, and an increase in local and systemic inflammatory mediators, which include proinflammatory cytokines [eg, interleukins such as interleukin (IL)-6 and IL-8 and tumor necrosis factor-a (1, 2, 6)].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting

Gullett

Hebbar

Ziegler

2010

The American Journal of Clinical Nutrition

View full text Add to dashboard Cite

This article and others that focused on the clinical features, mechanisms, and epidemiology of skeletal muscle loss and wasting in chronic diseases, which include chronic kidney disease, cancer, and AIDS, were presented at a symposium entitled "Cachexia and Wasting: Recent Breakthroughs in Understanding and Opportunities for Intervention," held at Experimental Biology 2009. The clinical and anabolic efficacy of specific growth factors and anabolic steroids (eg, growth hormone, testosterone, megestrol acetate) in malnutrition and other catabolic states has been the subject of considerable research during the past several decades. Research on the effects of these agents in cachexia or wasting conditions, characterized by progressive loss of skeletal muscle and adipose tissue, focused on patients with AIDS in the early 1990s, when the devastating effects of the loss of body weight, lean body mass, and adipose tissue were recognized as contributors to these patients' mortality. These same agents have also been studied as methods to attenuate the catabolic responses observed in cancer-induced cachexia and in wasting induced by chronic obstructive pulmonary disease, congestive heart failure, renal failure, and other conditions. This article provides an updated review of recent clinical trials that specifically examined the potential therapeutic roles of growth hormone, testosterone, oxandrolone, and megestrol acetate and emerging data on the orexigenic peptide ghrelin, in human cachexia and wasting.Am J Clin Nutr 2010;91(suppl):1143S-7S.

show abstract

Approach to the Patient with Unintentional Weight Loss

Subramanian

Rhodes

2015

Yamada' S Textbook of Gastroenterology

View full text Add to dashboard Cite

Recent insights on chronic heart failure, cachexia and nutrition

Cited by 18 publications

References 40 publications

Tonic Chemoreflex Activation Contributes to Increased Sympathetic Nerve Activity in Heart Failure–Related Anemia

Tonic Chemoreflex Activation Contributes to Increased Sympathetic Nerve Activity in Heart Failure–Related Anemia

Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting

Approach to the Patient with Unintentional Weight Loss

Contact Info

Product

Resources

About